顺铂
结直肠癌
黄芪甲苷
活力测定
细胞毒性
医学
癌症研究
MTT法
细胞生长
免疫印迹
癌细胞
药理学
癌症
下调和上调
内科学
细胞
肿瘤科
化疗
生物
体外
化学
生物化学
基因
高效液相色谱法
色谱法
作者
Tao Xie,Yao Li,Shilei Li,Haifeng Luo
出处
期刊:Oncology Research
[Cognizant, LLC]
日期:2016-10-27
卷期号:24 (6): 447-453
被引量:29
标识
DOI:10.3727/096504016x14685034103590
摘要
Although astragaloside IV exhibits anti-inflammation, immunoregulatory, and anticancer properties, the chemosensitization effects of astragaloside IV in colorectal cancer have never been reported. Our study tested whether astragaloside could increase cisplatin sensitivity in colorectal cancer. CCK-8 assay was used to measure the cell viability of colorectal cancer cells. Quantitative real-time PCR and Western blot were performed to determine the mRNA and protein expression, respectively. Our data revealed that astragaloside IV administration significantly suppressed the cell growth of colorectal cancer cells, whereas no obvious cytotoxicity of astragaloside IV was observed in nonmalignant colonic cells. In addition, combined treatment with astragaloside IV dramatically elevated the chemosensitivity of colorectal cancer cells to cisplatin. Mechanical investigation revealed that the mRNA and protein expression of NOTCH3 was significantly lower in cisplatin and astragaloside IV-treated cells compared with cells treated with cisplatin alone. On the contrary, no obvious changes in tumor cell growth were shown after upregulation of NOTCH3 whether in the presence or absence of astragaloside IV. Thus, our data demonstrate that astragaloside IV increases the chemosensitivity of colorectal cancer cells to cisplatin, at least partly, through inhibition of NOTCH3. This study suggests that combined therapy with astragaloside IV might be a novel therapeutic approach for colorectal cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI